In short
A groundbreaking Phase 3 clinical trial is underway to assess the effectiveness and safety of Ribitol (BBP-418) in patients with Limb Girdle Muscular Dystrophy Type 2I (LGMD2I). This study aims to provide valuable insights into a potential treatment for this rare genetic disorder, offering hope to those affected by LGMD2I. The trial involves long-term administration of Ribitol to patients aged 12 to 60, covering a significant portion of diagnosed individuals based on the disease's epidemiology.
At a glance
- Study Type
- Phase 3, randomized, placebo-controlled, double-blind clinical trial
- Drug
- Ribitol (BBP-418)
- Condition
- Limb Girdle Muscular Dystrophy Type 2I (LGMD2I)
- Participant Age Range
- 12 to 60 years (18 to 60 years in EU region)
- Treatment Duration
- 36 months
- Primary Outcomes
- Change in North Star Assessment, Safety assessment
- Secondary Outcomes
- 10-meter walk test, Pulmonary function, Upper limb performance
- Other Outcomes
- Changes in glycosylated Alpha dystroglycan levels
- Randomization
- 2:1 ratio (drug:placebo)
What is RIBITOL?
RIBITOL, also known as BBP-418, is a new drug being studied for the treatment of a specific type of muscular dystrophy. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), also referred to as LGMD2I/R9.
What condition does RIBITOL target?
RIBITOL is specifically designed to treat Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is a rare genetic disorder that causes progressive muscle weakness, primarily affecting the muscles around the shoulders and hips. The condition can vary in severity and age of onset, but it typically leads to difficulty with mobility and daily activities over time.
How does RIBITOL work?
While the exact mechanism of action is not fully described in the provided information, RIBITOL is believed to work by addressing the underlying genetic defect in LGMD2I. The drug appears to target a protein called alpha-dystroglycan, which plays a crucial role in muscle function. By potentially increasing the glycosylation (a process of adding sugar molecules) of alpha-dystroglycan, RIBITOL may help improve muscle strength and function in patients with LGMD2I.
Current Clinical Trial
RIBITOL is currently being evaluated in a Phase 3 clinical trial. This is an advanced stage of research that aims to confirm the drug's effectiveness and safety in a larger group of patients. Here are some key points about the trial:
- It is a randomized, placebo-controlled, double-blind study. This means that participants are randomly assigned to receive either RIBITOL or a placebo, and neither the patients nor the researchers know who is receiving which treatment. This design helps ensure unbiased results.
- The study includes patients aged 12 to 60 years old, covering the majority of diagnosed LGMD2I patients.
- Participants are divided into groups based on their specific genetic mutation, age, and other factors to ensure a balanced evaluation.
How is RIBITOL administered?
RIBITOL is provided as granules for oral solution. Here's what patients should know about its administration:
- The drug comes in sachets (small packets) containing granules.
- These granules are mixed with water to create a solution that can be taken by mouth.
- The dose is determined based on the patient's weight, with options of 9 grams or 12 grams, taken twice daily.
How is RIBITOL's effectiveness measured?
The clinical trial is using several methods to assess how well RIBITOL works. These include:
- North Star Assessment for Limb Girdle Muscular Dystrophy: This is the primary measure, looking at changes in muscle function over 36 months of treatment.
- 10-meter walk test: This measures how quickly patients can walk a short distance.
- Pulmonary function tests: These assess how well the lungs are working.
- Performance of Upper Limb scale: This evaluates arm and hand function.
- Biomarker tests: These look at changes in specific proteins (alpha-dystroglycan) in the body that are related to LGMD2I.
Safety Monitoring
As with any new medication, monitoring for side effects is crucial. The study is carefully tracking the frequency and severity of any adverse events that occur during the 36-month treatment period. This information will help determine the overall safety profile of RIBITOL.